Maria V. Yelshanskaya

Maria V. Yelshanskaya

Auto-generated profile, based on publicly available information

Maria V. Yelshanskaya

Department of Biochemistry and Molecular Biophysics, Columbia University, New York, USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 May 2024 in Science Advances
Verified
Journal Article
Open access
KNKirill Nadezhdin
Kirill Nadezhdin
ANArthur Neuberger
Arthur Neuberger
LKLena S. Khosrof
Lena S. Khosrof
ITIrina A. Talyzina
Irina A. Talyzina
JKJeffrey Khau
Jeffrey Khau
ASAlexander I. Sobolevsky
Alexander I. Sobolevsky
TRPV3 represents both temperature- and ligand-activated transient receptor potential (TRP) channel. Physiologically relevant opening of TRPV3 channels by heat has been captured structurally, while opening by agonists has only been observed in structures of mutant channels. Here, we present cryo-EM structures that illuminate opening and inactivation of wild-type human TRPV3 in response to binding of two types of agonists: either the natural cannabinoid tetrahydrocannabivarin (THCV) or synthetic agonist 2-aminoethoxydiphenylborane (2-APB). We found that THCV binds to the vanilloid site, while 2-APB binds to the S1-S4 base and ARD-TMD linker sites. Despite binding to distally located sites, both agonists induce similar pore opening and cause dissociation of a lipid that occupies the vanilloid site in their absence. Our results uncover different but converging allosteric pathways through which small-molecule agonists activate TRPV3 and provide a framework for drug design and understanding the role of lipids in ion channel function.

22 September 2020 in British Journal of Pharmacology
Verified
Journal Article
Closed access
PDF file
MYMaria V. Yelshanskaya
Maria V. Yelshanskaya
ASAppu K. Singh
Appu K. Singh
CNChamali Narangoda
Chamali Narangoda
RWRobin williams
Robin williams
MKMaria G. Kurnikova
Maria G. Kurnikova
ASAlexander I. Sobolevsky
Alexander I. Sobolevsky

1 October 2021 in STAR Protocols
Verified
Journal Article
Open access
SGShanti Pal Gangwar
Shanti Pal Gangwar
MGMarriah N. Green
Marriah N. Green
MYMaria V. Yelshanskaya
Maria V. Yelshanskaya
ASAlexander I. Sobolevsky
Alexander I. Sobolevsky
Ionotropic glutamate receptors (iGluRs) are ligand-gated ion channels that play crucial roles in the central nervous system. iGluR homologs, termed glutamate receptor-like channels (GLRs), have been found in plants. Investigating the structural and functional relationship between iGluRs and GLRs was limited by GLR protein expression, purification, and structural characterization. Here, we provide a detailed protocol for Arabidopsis thaliana GLR3.4 (AtGLR3.4) expression in a mammalian cell line and purification for structure determination by cryogenic electron microscopy (cryo-EM).

9 September 2026 in Nature Structural & Molecular Biology
Verified
Journal Article
Open access
PDF file
TNThomas P. Newton
Thomas P. Newton
MAMuhammed Aktolun
Muhammed Aktolun
MYMaria V. Yelshanskaya
Maria V. Yelshanskaya
AAAlexey A. Alekseev
Alexey A. Alekseev
LYLaura Y. Yen
Laura Y. Yen
ASAlexander I. Sobolevsky
Alexander I. Sobolevsky
AMPA receptors (AMPARs) mediate fast excitatory neurotransmission. Gating of AMPARs starts with agonist binding and transition into a non-conducting pre-active state, followed by transition into conducting open or non-conducting desensitized states. While the terminal apo, open and desensitized states have been structurally characterized, the intermediate pre-active state has remained an enigma. Compared to full agonist glutamate, partial agonists reduce the maximal occupancy of the open state and increase the probability of the pre-active state occurrence. Here we use different partial agonists and time-resolved cryo-electron microscopy (cryo-EM) to capture a structural ensemble of GluA2–γ2 AMPAR complexes in the closed apo, pre-active, open and desensitized states. Binding of partial agonists to the ligand-binding domain (LBD) results in different extents of LBD clamshell closure, with closures exceeding a threshold of ~17° resulting in the open and desensitized states and smaller closures stabilizing the pre-active state. The pre-active state has a distinct gate conformation intermediate between the other two discrete states, completely open and closed. Combined with single-channel current recordings and molecular dynamics simulations, our structural results reveal the complete gating pathway of AMPARs and shed light on the molecular mechanisms of partial agonism and pre-activation.

3 September 2026 in Nature Communications
Verified
Journal Article
Open access
PDF file
TNThomas P. Newton
Thomas P. Newton
MYMaria V. Yelshanskaya
Maria V. Yelshanskaya
MAMuhammed Aktolun
Muhammed Aktolun
SGShanti Pal Gangwar
Shanti Pal Gangwar
LYLaura Y. Yen
Laura Y. Yen
ASAlexander I. Sobolevsky
Alexander I. Sobolevsky
AMPA receptors (AMPARs) facilitate excitatory neurotransmission and are implicated in neurological and neuropsychiatric disorders. Binding of the neurotransmitter glutamate triggers AMPAR activation, which is modulated by potentiating and inhibitory auxiliary subunits. While modulation by potentiating auxiliary subunits has been studied extensively, activation involving inhibitory subunits has not been examined. Here, we present structures of the activated GluA2 AMPAR alone and in complex with inhibitory subunits GSG1L or γ5. Our results suggest that gating kinetics strongly depend on auxiliary subunit identity, while pore size and conductance do not. We find that receptor deactivation becomes slower if an auxiliary subunit promotes tightening of the interface between two ligand-binding domain dimers during activation. In addition, we functionally characterize the effects of epilepsy-associated disease mutations on AMPAR activation and desensitization kinetics, displaying strong dependence on the type of bound auxiliary subunit. Modulation by auxiliary subunits therefore has to be considered when designing AMPAR-targeting therapeutics.